NEWS On the Health Affairs Blog: Blumenthal, Linthicum and Kamal-Bahl Address Outcomes-Based Pricing Agreements 4/03/17

In the latest post on the IVI-sponsored Health Affairs blog series, Daniel Blumenthal, IVI Director of Scientific Communications Mark Linthicum, and IVI Panel of Health Advisors member Sachin Kamal-Bahl discuss challenges in establishing outcomes-based pricing agreements for pharmaceuticals and potential strategies for overcoming obstacles. Strategies discussed include: focusing on legal and regulatory changes, increased information sharing, and more investment in infrastructure and human capital.

Read more here.